SS-31 Reconstitution Calculator

Yes, but narrowly. Elamipretide (SS-31; marketed as Forzinity) received US accelerated approval in 2025 for Barth syndrome to improve muscle strength in adults and pediatric patients weighing at least 30 kg (regulatory/human clinical evidence). It is not broadly approved for anti-aging, athletic recovery, general fatigue, neuroprotection, or weight loss uses discussed in peptide circles.

SS-31 is a mitochondria-targeting aromatic-cationic tetrapeptide that binds cardiolipin-rich inner mitochondrial membranes and stabilizes cristae/membrane architecture rather than acting through a classical receptor (mechanistic/human translational evidence). Reported downstream effects include improved oxidative phosphorylation efficiency, reduced proton leak, lower ROS amplification, and better ATP production when there is still salvageable mitochondrial function (mechanistic/RCT/animal).

Subcutaneous is the established route. Approved Barth syndrome use is once-daily subcutaneous dosing, and clinical development has primarily used SC or IV administration; peptides like SS-31 are not considered reliably orally bioavailable (human clinical evidence/mechanistic). Community use therefore centers on SC daily dosing, typically 4–40 mg/day depending on goal and body size (community protocol). Oral capsules sold online are not supported by the cited clinical literature (review/human translational evidence).

For the approved indication, labeling summarized in recent reviews specifies 40 mg subcutaneously once daily for eligible Barth syndrome patients ≥30 kg (human clinical evidence). Outside that setting, community protocols commonly use 5–10 mg SC daily for general mitochondrial support, 10–20 mg SC daily for more symptomatic fatigue/exercise intolerance, and occasional loading phases up to 20–40 mg/day for 4–8 weeks before stepping down (community protocol). Human randomized evidence also shows mitochondrial ATP production improved after a single dose in older adults, but that study does not establish a broad outpatient DIY dosing standard by itself (RCT).

Longer exposure appears more relevant than single-dose use for functional outcomes. In Barth syndrome, benefit signals became clearer with extended treatment and open-label continuation, consistent with gradual membrane-architecture rescue rather than an immediate stimulant effect (human clinical evidence). Practical use is usually 6–12 weeks for a trial, then continuation if there is objective benefit in fatigue, exercise tolerance, or recovery markers (community protocol). Chronic daily use is feasible in the approved setting, but long-term non-Barth safety remains less certain than short- to medium-term use (review/human evidence).

Injection-site reactions are the most common and include erythema, pain, pruritus, swelling, induration, and small hematomas; these were generally mild to moderate in reported human experience (human clinical evidence/review). Less common symptoms described in reviews include headache, nausea, dizziness, and fatigue (human clinical evidence/review). If someone cannot tolerate repeated SC injections, adherence usually fails before systemic toxicity becomes the main issue (practical inference from human safety profile).

Evidence is mixed and indication-dependent. In older adults, a randomized trial showed improved in vivo skeletal-muscle mitochondrial ATP production after a single dose (RCT). In preclinical HFpEF models, elamipretide improved skeletal muscle force, fiber function, and mitochondrial measures (animal), but myocardial bioenergetic gains in HFpEF did not clearly translate into functional cardiac benefit in another model, suggesting organ-level fibrosis/remodeling can block clinical translation (animal/mechanistic). For athletic recovery or musculoskeletal healing in healthy people, human evidence is weak to absent; most claims are extrapolation from mitochondrial biology and animal data (review).

SS-31 is the most clinically advanced cardiolipin-directed mitochondrial peptide in this corpus and has actual regulatory approval in a rare mitochondrial disease, which neither MOTS-c nor generic antioxidant supplements match here (human clinical/regulatory evidence). Mechanistically, SS-31 is a membrane-stabilizer at cardiolipin-rich inner mitochondrial membranes, while MOTS-c is framed as a mitochondria-derived signaling peptide affecting metabolic regulation, and MitoQ is a small-molecule mitochondria-targeted antioxidant rather than a cardiolipin-binding peptide (review/mechanistic). If the goal is a peptide with the strongest human translational support for mitochondrial dysfunction, SS-31 currently leads this group in the provided literature (review/regulatory).

The corpus here does not provide detailed storage logistics. In practice, users follow pharmacy-specific compounding or product instructions, keep lyophilized peptide protected from heat/light, refrigerate after reconstitution, and use insulated transport for travel when possible (practitioner consensus). For approved commercial product, follow the dispensing label rather than generic peptide-storage advice, because formulation and stability can differ (practical guidance).